Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sim1 who wrote (486)	4/15/1999 7:18:00 PM
From: BRAVEHEART	Read Replies (3) of 1494

Hi Stuart, The actual peripheral neuropathy market is extremely large. Memantine is targeting just painful diabetic peripheral neuropathies. I say just with some hesitation because it is still a significant size market. There are many causes of peripheral neuropathies. Disease states and chemical side effects account for a verity of neuropathies whose pathways of treatment can vary. I know this does not answer your question. In fact it raises a much larger question. Which other peripheral neuropathies might Memantine effectively target. Furthermore, if and when Memantine gets approval will there be much off label usage for the treatment for some of the other painful neuropathy conditions. Stuart IMO you touched on the tip of the iceburg of potential additional uses of Memantine. BEST WISHES Jeffrey

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next